Three Case Reports of Hand-Foot Syndrome with Gefitinib

Hand-Foot Syndrome (HFS) is commonly reported in treatment with liposomal doxorubicin (LD) and capecitabine. We present 3 cases of HFS recall with gefitinib after previous LD therapy. The first 2 cases, in patients with head and neck cancer previously treated with paclitaxel and LD, developed on subsequent therapy with gefitinib. One patient had previously developed HFS on LD and the other had not. In both patients HFS resolved after stopping gefitinib. The third case is of a patient with ovarian cancer, also treated with gefitinib after LD, who developed HFS recall which resolved after gefitinib withdrawal. HFS can occur with gefitinib in patients who have been previously exposed to agents known to cause HFS.

[1]  Alain Spatz,et al.  Cutaneous side-effects of kinase inhibitors and blocking antibodies. , 2005, The Lancet. Oncology.

[2]  I. Kurokawa,et al.  Purpuric drug eruption possibly due to gefinitib (Iressa®) , 2004, International journal of dermatology.

[3]  M. Ychou,et al.  Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours , 2004, The British journal of dermatology.

[4]  M. Dimopoulos,et al.  Pegylated liposomal doxorubicin hydrochloride (PLD) and paclitaxel in recurrent or metastatic head and neck carcinoma: a phase I/II study conducted by the Hellenic Cooperative Oncology Group (HeCOG) , 2004, Anti-cancer drugs.

[5]  J. López-Picazo,et al.  Acneiform lesions secondary to ZD1839, an inhibitor of the epidermal growth factor receptor , 2004, Clinical and experimental dermatology.

[6]  J. Cortes,et al.  Chemotherapy-Induced Palmar-Plantar Erythrodysesthesia Syndrome – Recall Following Different Chemotherapy Agents , 2002, Investigational New Drugs.

[7]  David Cella,et al.  Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. , 2003, JAMA.

[8]  Masahiro Fukuoka,et al.  Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  M. Perry.  The Chemotherapy Source Book , 1992, Annals of Internal Medicine.

[10]  E. Nagore,et al.  Antineoplastic Therapy—Induced Palmar Plantar Erythrodysesthesia (‘Hand-Foot’) Syndrome , 2000, American journal of clinical dermatology.

[11]  A. Buzaid,et al.  Phase II trial of doxil for patients with metastatic melanoma refractory to frontline therapy. , 1999, Oncology reports.

[12]  A. Norman,et al.  Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  D. Thamm,et al.  Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: a randomized, double-blind clinical trial using a canine model. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  D. Calista,et al.  Cytarabine‐induced acral erythema: a localized form of toxic epidermal necrolysis? , 1998, Journal of the European Academy of Dermatology and Venereology : JEADV.

[15]  R. Rosso,et al.  Hand-foot syndrome induced by high-dose, short-term, continuous 5-fluorouracil infusion. , 1997, European journal of cancer.

[16]  L J Liang,et al.  Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  F M Muggia,et al.  Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  D. V. Von Hoff,et al.  Acute cutaneous reactions to docetaxel, a new chemotherapeutic agent. , 1995, Archives of dermatology.

[19]  S. Bretti,et al.  Palmar-plantar erythrodysestasia syndrome associated with 5-fluorouracil treatment. , 1993, Anticancer Research.

[20]  B. Samuels,et al.  Continuous venous infusion of doxorubicin in advanced sarcomas. , 1987, Cancer treatment reports.

[21]  J. Roujeau,et al.  Cancer chemotherapy and acral erythema. , 1982, Annals of internal medicine.